Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 197.22M | 153.56M | 124.45M | 48.58M | -75.86M |
| Total Depreciation and Amortization | 32.91M | 33.22M | 33.78M | 34.19M | 34.91M |
| Total Amortization of Deferred Charges | 4.56M | 3.79M | 3.22M | 2.91M | 2.69M |
| Total Other Non-Cash Items | -100.53M | -65.46M | -99.42M | -43.42M | 86.23M |
| Change in Net Operating Assets | -2.44M | -1.61M | -12.67M | -10.35M | 7.38M |
| Cash from Operations | 131.71M | 123.50M | 49.36M | 31.92M | 55.36M |
| Capital Expenditure | -278.00K | -466.00K | -452.00K | -1.16M | -1.74M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -8.09M | -8.09M | -8.09M | -- | -- |
| Other Investing Activities | -136.42M | -468.01M | -368.79M | -396.69M | -89.17M |
| Cash from Investing | -144.78M | -476.56M | -377.32M | -397.84M | -90.90M |
| Total Debt Issued | 1.16B | 460.00M | 460.00M | 460.00M | -- |
| Total Debt Repaid | -309.07M | -113.28M | -113.28M | -113.28M | -30.00K |
| Issuance of Common Stock | 51.30M | 50.93M | 47.50M | 60.65M | 90.33M |
| Repurchase of Common Stock | -97.64M | -37.44M | -24.60M | -26.19M | -11.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 145.69M | 58.62M | 58.60M | 59.10M | 6.51M |
| Cash from Financing | 950.28M | 418.84M | 428.22M | 440.28M | 85.72M |
| Foreign Exchange rate Adjustments | -995.00K | 1.26M | 2.36M | 1.40M | 2.18M |
| Miscellaneous Cash Flow Adjustments | 2.82M | 78.00K | 0.00 | 0.00 | -2.82M |
| Net Change in Cash | 939.03M | 67.11M | 102.62M | 75.76M | 49.53M |